Free Trial

Cantor Fitzgerald Reduces Earnings Estimates for AbbVie

AbbVie logo with Medical background

AbbVie Inc. (NYSE:ABBV - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a report released on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now expects that the company will post earnings of $11.84 per share for the year, down from their prior forecast of $12.31. Cantor Fitzgerald currently has a "Overweight" rating and a $210.00 target price on the stock. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Cantor Fitzgerald also issued estimates for AbbVie's FY2026 earnings at $14.09 EPS.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same quarter in the previous year, the firm posted $2.31 earnings per share. The company's revenue for the quarter was up 8.4% on a year-over-year basis.

ABBV has been the subject of a number of other reports. BNP Paribas raised AbbVie to a "hold" rating in a research report on Thursday, May 8th. Guggenheim increased their price target on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Citigroup upped their price objective on shares of AbbVie to $205.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and a consensus target price of $211.29.

Get Our Latest Stock Report on ABBV

AbbVie Stock Performance

Shares of NYSE:ABBV traded down $2.68 during mid-day trading on Thursday, reaching $192.32. The company had a trading volume of 4,990,162 shares, compared to its average volume of 6,311,659. AbbVie has a one year low of $163.81 and a one year high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. The company's 50-day moving average price is $187.01 and its 200-day moving average price is $189.11. The firm has a market cap of $339.71 billion, a price-to-earnings ratio of 81.84, a PEG ratio of 1.28 and a beta of 0.48.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be given a $1.64 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.41%. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

Hedge Funds Weigh In On AbbVie

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABBV. Norges Bank purchased a new stake in AbbVie in the fourth quarter valued at approximately $4,459,385,000. GAMMA Investing LLC increased its holdings in shares of AbbVie by 25,841.6% in the 1st quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company's stock worth $2,144,382,000 after buying an additional 10,195,284 shares during the last quarter. Nuveen LLC purchased a new stake in shares of AbbVie during the 1st quarter valued at $1,819,154,000. FMR LLC lifted its holdings in shares of AbbVie by 32.8% during the 4th quarter. FMR LLC now owns 18,097,375 shares of the company's stock worth $3,215,903,000 after acquiring an additional 4,466,971 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of AbbVie by 550.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company's stock worth $804,116,000 after acquiring an additional 3,666,521 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Featured Articles

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines